Amphastar Pharmaceuticals, Inc. $AMPH Stock: Royce & Associates LP Reduces Stake

Royce & Associates LP lessened its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 72.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 81,782 shares of the company’s stock after selling 212,976 shares during the quarter. Royce & Associates LP’s holdings in Amphastar Pharmaceuticals were worth $2,111,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Eurizon Capital SGR S.p.A. bought a new position in shares of Amphastar Pharmaceuticals in the third quarter worth approximately $33,000. Fulcrum Asset Management LLP raised its stake in Amphastar Pharmaceuticals by 473.9% in the third quarter. Fulcrum Asset Management LLP now owns 10,044 shares of the company’s stock valued at $268,000 after purchasing an additional 8,294 shares in the last quarter. Hohimer Wealth Management LLC lifted its position in Amphastar Pharmaceuticals by 5.6% during the third quarter. Hohimer Wealth Management LLC now owns 13,867 shares of the company’s stock valued at $358,000 after purchasing an additional 739 shares during the last quarter. Bridge City Capital LLC lifted its position in Amphastar Pharmaceuticals by 13.3% during the third quarter. Bridge City Capital LLC now owns 383,901 shares of the company’s stock valued at $9,908,000 after purchasing an additional 45,193 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Amphastar Pharmaceuticals in the 3rd quarter worth approximately $56,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 9th. Barclays lifted their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 18th. Piper Sandler cut their target price on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Wells Fargo & Company increased their target price on Amphastar Pharmaceuticals from $20.00 to $25.00 and gave the company an “equal weight” rating in a research note on Friday, November 6th. Seven research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $23.33.

Check Out Our Latest Analysis on AMPH

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William Peters sold 16,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $28.03, for a total transaction of $448,480.00. Following the transaction, the chief financial officer directly owned 168,707 shares of the company’s stock, valued at approximately $4,728,857.21. This trade represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Rong Zhou sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total transaction of $239,400.00. Following the completion of the sale, the executive vice president owned 169,203 shares of the company’s stock, valued at approximately $4,050,719.82. The trade was a 5.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock worth $1,232,836 over the last three months. Insiders own 29.60% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of NASDAQ AMPH opened at $28.11 on Friday. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of 11.09, a P/E/G ratio of 5.25 and a beta of 0.93. The company has a current ratio of 3.32, a quick ratio of 2.36 and a debt-to-equity ratio of 0.75. Amphastar Pharmaceuticals, Inc. has a 1-year low of $16.65 and a 1-year high of $31.00. The stock’s 50-day moving average is $26.42 and its 200 day moving average is $22.44.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.28. The business had revenue of $207.61 million during the quarter, compared to analyst estimates of $197.52 million. Amphastar Pharmaceuticals had a return on equity of 15.31% and a net margin of 13.27%. On average, sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.68 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

(Free Report)

Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures and markets generic and proprietary medicines, with a focus on products that can be technically challenging to produce. Its offerings include injectable, inhalation and intranasal medicines, as well as insulin active pharmaceutical ingredients. The company’s products include treatments and emergency medicines such as enoxaparin, glucagon and epinephrine products. Amphastar also markets BAQSIMI, a nasal powder used to treat severe low blood sugar, and Primatene MIST, an over-the-counter asthma inhaler.

Featured Articles

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.